Mary Ann Gray, Ph.D ., joined the Compass Board of Directors in April of 2022. Dr. Gray has been President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm, since September 2003. Previously, she served as senior analyst and portfolio manager of Federated Kaufmann Fund ( Federated ). Prior to Federated, she served as a biotechnology equity research analyst at multiple firms. Earlier in her career, she worked as a senior scientist both at Schering Plough Research and NeoRx Corporation. Dr. Gray currently serves on the board of directors of BioAtla, Inc. (Nasdaq: BCAB) and Keros Therapeutics, Inc. (Nasdaq: KROS). From December of 2019 to March of 2026, Dr. Gray served on the board of Rapt Therapeutics, Inc. (Nasdaq: RAPT) until its acquisition by GSK plc (LSE/NYSE: GSK), and she has previously served on the board of directors of many public and private biotechnology companies, including Palisade Bio, Inc. (Nasdaq: PALI) from April of 2021 to March of 2024 and Sarepta Therapeutics, Inc. (Nasdaq: SRPT) from December of 2018 to June of 2022. Dr. Gray earned a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. We believe that Dr. Gray s extensive experience in the biotechnology and biopharmaceutical industry experience, including serving on the boards of publicly traded life sciences companies and high-level accounting and financial expertise, qualifies her to serve on our Board of Directors.